HIHideaki Ishii

Hideaki Ishii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideaki Ishii has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Immunohistochemical and ultrastructural investigation on cutaneous neuroendocrine carcinoma: report of a case and review of the literature

    by Hideaki Ishii, Takashi Joshita, Nagahisa Matsuyama, Takashi Uchida, Akio Ishikawa, Yoshiro Ebihara

    We report a tumor in an 80-year-old man that was difficult to distinguish from other tumors, i.e., small cell carcinoma of the lung, PNET/Ewing tumor, malignant lymphoma, or malignant melanoma (amelanotic), and which was finally identified as cutaneous neuroendocrine carcinoma using immunohistochemical and ultrastructural methods. Autopsy did not show any tumors in the lungs, excluding the possibility of small cell carcinoma of the lung. Immunohistochemistry tests gave negative results for LCA, UCHL-1, CD3, and CD20, thereby excluding malignant lymphoma, and the negative results for S-100 protein and HMB-45 ruled out malignant melanoma. The possibility of PNET/Ewing sarcoma was also excluded because of negativity for CD99. In addition, the ultramicrostructure showed intercellular junctional complexes and neuroendocrine granules, indicating that the tumor had characteristics of both epithelial and neuroendocrine tissues. We therefore diagnosed the primary carcinoma of the skin as cutaneous neuroendocrine carcinoma.


  • Apoptosis and cell proliferation in the development of gastric carcinomas: Associations with c‐myc and p53 protein expression

    by Hideaki H Ishii, Glenda C Gobé, Wenshen Pan, Juichi Yoneyama, Yoshiro Ebihara

    Background and Aim: Patients with gastric carcinomas have a poor prognosis and low survival rates. The aim of the present paper was to characterize cellular and molecular properties to provide insight into aspects of tumor progression in early compared with advanced gastric cancers. Methods: One hundred and nine graded gastric carcinomas (early or advanced stage, undifferentiated or differentiated type) with paired non‐cancer tissue were studied to define the correlation between apoptosis (morphology, terminal deoxyribonucleotidyl transferase‐mediated dUTP–digoxigenin nick end‐labeling), cell proliferation (Ki‐67 expression, morphology) and expression and localization of two proteins frequently having altered expression in cancers, namely p53 and c‐myc. Results: Overall, apoptosis was lower in early stage, differentiated and undifferentiated gastric carcinomas compared with advanced‐stage cancers. Cell proliferation was comparatively high in all stages. There was a high level of p53 positivity in all stages. Only the early‐ and advanced‐stage undifferentiated cancers that were p53 positive had a significantly higher level of apoptosis (P < 0.05). Cell proliferation was significantly greater (P < 0.05) only in the early undifferentiated cancers that had either c‐myc or p53‐positivity. Conclusions: The results indicate that low apoptosis and high cell proliferation combine to drive gastric cancer development. The molecular controls for high cell proliferation of the early stage undifferentiated gastric cancers involve overexpression of both p53 and c‐myc. Overexpression of p53 may also control cancer development in that its expression is associated with higher levels of apoptosis in early and late‐stage undifferentiated, cancers.© 2002 Blackwell Publishing Asia Pty Ltd


  • Interrelationship between Epstein–Barr virus infection in gastric carcinomas and the expression of apoptosis‐associated proteins

    by H Ishii, G Gobé, Y Kawakubo, Y Sato, Y Ebihara

    Aims: Epstein–Barr virus (EBV) and its associated proteins may be protective against the occurrence of apoptosis that would normally inhibit cancer development and progression. Alternatively, the viral infection may cause altered or mutated expression of oncogenes or tumour suppressor genes that are necessary for tumour development, an action that may also involve apoptosis. In this study, a relationship was sought between occurrence of EBV infection, expression of apoptosis‐associated proteins (tumour suppressor gene p53 and oncogenes c‐myc and bcl‐2) and levels of cell death (apoptosis or necrosis) in 119 cases of gastric carcinoma.Methods and results: The EBV status of the gastric carcinomas (using the EBV‐encoded small RNA I (EBER‐1) and in‐situ hybridization), stage and grade of tumour and sex of patients were compared for bcl‐2, p53 and c‐myc expression patterns. EBER‐1 was detected in approximately 20% of cases studied. There was no significant correlation between levels of cell death in the tumour tissue and EBV status. In the protein analyses, development and progression of gastric carcinoma, with or without EBV infection, was independent of bcl‐2 expression. However, in gastric cancers with EBV infection, p53 overexpression was inhibited and c‐myc expression was increased in early stage cancers, in comparison with decreased c‐myc expression in late stage cancers.Conclusions: The p53 and c‐myc expression patterns indicate that EBV‐infected gastric carcinomas are less likely to have a natural regression via apoptosis at an early stage and explain, in part, the resistance to treatment of late stage of gastric cancers.